Monday, January 30, 2012
Seattle Genetics Inc., of San Francisco, and Millennium, of Cambridge, Mass., a unit of Takeda Pharmaceuticals Co. Ltd., reported interim results from 32 patients treated to date in a Phase I trial of Adcetris (brentuximab vedotin) in combination with or sequentially with chemotherapy in newly diagnosed systemic anaplastic large-cell lymphoma (sALCL) and other CD30-postive mature T-cell lymphoma patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.